Xu Jinghe, deputy commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Yasuhiro Fujiwara, chief executive of Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on Jan 7, 2020.
The National Medical Products Administration (NMPA) has given the go-ahead for the launch of China's first self-developed 13-valent pneumonia vaccine to better protect babies from a leading cause of death.
A conference for publicizing China’s newly-revised drug administration law, co-sponsored by the NMPA, the EU to China and the Danish Embassy in China, was held on Dec 11 in Beijing, at which the law was introduced to the EU embassies in China and representatives of foreign-invested enterprises.
China has required the completion of a national vaccine tracking system before March 31, 2020, to enable the whole-process traceability of all vaccines on the market, according to a recent circular.
The number of licensed pharmacists totaled over 1.03 million by the end of November, data from the National Medical Products Administration showed.
China's revised drug administration law, adopted by the top legislature in August, went into effect on Dec 1, as part of the country's efforts to strengthen supervision to ensure drug safety.